Anemia Management

Introduction to Anemia Management

• The American Society of Clinical Oncology recommends that erythropoiesis-stimulating agents (ESAs) should only be offered to patients with chemotherapy-associated anemia whose cancer treatment is not curative in intent and whose hemoglobin has declined to <10 g/dL, or to patients with chronic kidney disease (CKD) with hemoglobin <10 g/dL, targeting a hemoglobin level of 10-11.5 g/dL to reduce transfusion requirements while minimizing cardiovascular risks 1, 2
• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend a target hemoglobin range of 10-11.5 g/dL to reduce thrombotic risk while maintaining adequate oxygen delivery in CKD patients with anemia, with a strength of evidence rated as moderate 3, 4

Patient Selection

• Appropriate candidates for ESAs include patients receiving myelosuppressive chemotherapy with non-curative intent and hemoglobin <10 g/dL, as recommended by the American Society of Clinical Oncology 1, 2, 5
• The American Society of Clinical Oncology may offer ESAs to patients with lower-risk myelodysplastic syndrome (MDS) and serum erythropoietin ≤500 IU/L 1, 2
• Darbepoetin alfa is indicated for treating anemia in CKD patients with hemoglobin levels below 10 g/dL, with individualized dosing to maintain hemoglobin between 10-12 g/dL, while carefully balancing benefits against cardiovascular risks 6

Contraindications

• ESAs are contraindicated in patients receiving cancer treatment with curative intent, as stated by the American Society of Clinical Oncology 1, 2
• Darbepoetin is not recommended for use in acute renal failure due to insufficient evidence of benefit, and should be used with great caution in CKD patients with active malignancy, as recommended by KDIGO and ASCO/ASH guidelines 6, 7, 1

Monitoring and Dose Adjustments

• The American Society of Clinical Oncology recommends checking hemoglobin levels weekly until stabilized, then monthly, with a target hemoglobin of 10-11.5 g/dL (not to exceed 12 g/dL) 1, 5
• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest monitoring hemoglobin weekly until stabilized, then at least monthly, and adjusting the dose of darbepoetin alfa accordingly 3
• If hemoglobin increases <1 g/dL after 4 weeks, the dose should be increased according to FDA guidelines, as recommended by the American Society of Clinical Oncology 1, 2
• If hemoglobin increases >1 g/dL in 2 weeks or >2 g/dL in 4 weeks, the dose should be reduced by 25-50%, as stated by the American Society of Clinical Oncology 5, 8

Response Assessment

• If no response after 8-9 weeks of therapy, ESA should be discontinued, as recommended by the American Society of Clinical Oncology 8
• For cancer patients, ESA should be discontinued 4 weeks after completing chemotherapy, as stated by the American Society of Clinical Oncology 5

Safety Considerations

• ESAs increase the risk of thromboembolism by 67% compared to placebo, as reported by the American Society of Clinical Oncology 9
• There is an increased risk of death, myocardial infarction, and stroke when targeting hemoglobin >11 g/dL, although the specific guideline society is not mentioned in this case 1, 2
• The FDA black box warning notes increased risks for death, serious adverse cardiovascular reactions, and stroke when ESAs are administered to target hemoglobin levels greater than 11 g/dL, with a strength of evidence rated as high 3
• Pure red cell aplasia is a rare but potential side effect of ESAs, as reported by the American Society of Clinical Oncology 9

Special Considerations

• Using ESAs in curative cancer treatment settings increases mortality risk without benefit, as stated by the American Society of Clinical Oncology 1, 2
• Neglecting iron status can reduce ESA efficacy, and adequate iron supplementation is essential, as recommended by the American Society of Clinical Oncology 1, 5
• Ferritin levels should be ≥100 ng/mL and transferrin saturation ≥20% before starting ESA therapy, and iron supplementation should be considered to optimize response to ESA therapy, as recommended by KDIGO guidelines 6
• Regular monitoring of iron status, including ferritin and transferrin saturation, is recommended to ensure adequate iron stores before and during treatment 3
• Thromboprophylaxis should be considered if additional risk factors are present, due to the increased risk of thromboembolism with ESA therapy 1
• Monitor blood pressure regularly, watch for signs of thromboembolism, and be aware of the risk of pure red cell aplasia and ESA resistance 7, 1

Target Hemoglobin Ranges and Monitoring Recommendations

Cardiovascular Risk Factors

• For patients with additional cardiovascular risk factors, the KDIGO recommends following their guidelines for statin therapy, and consider low-dose aspirin (50-100 mg/day) for prevention of microvascular complications 4
• Thromboembolism risk is increased by 50-75% with ESA therapy, particularly in older patients with a history of cancer, and regular monitoring of blood pressure and watching for signs of thromboembolism are recommended 3

Cancer Considerations

• Patients with a history of cancer, even if in remission, require careful monitoring while on darbepoetin alfa, with regular assessments of their cancer status and adjustment of treatment as needed 3
• Use darbepoetin with extreme caution or avoid completely in CKD patients with active malignancy, history of stroke, or history of malignancy, weighing risks and benefits carefully 6, 10